We are live on ! Find out more
IRD

Opus Genetics

49 hedge funds and large institutions have $12.6M invested in Opus Genetics in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

199% more call options, than puts

Call options by funds: $239K | Put options by funds: $80K

0.32% more ownership

Funds ownership: 17.55%17.87% (+0.32%)

0% more funds holding

Funds holding: 4949 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

21% less capital invested

Capital invested by funds: $16M → $12.6M (-$3.38M)

Holders
49
Holders Change
Holders Change %
0%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
11
Reduced
12
Closed
11
Calls
$239K
Puts
$80K
Net Calls
+$159K
Net Calls Change
-$1.22M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.88M -$109K -27,073 -3%
RHJA
2
Rice Hall James & Associates
California
$2.78M -$83K -20,658 -2%
MCM
3
MAI Capital Management
Ohio
$1.53M -$118K -29,371 -6%
RB
4
Richmond Brothers
Michigan
$1.23M +$105K +26,143 +8%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$734K +$101K +25,064 +13%
KCM
6
Knoll Capital Management
Florida
$335K
BlackRock
7
BlackRock
New York
$313K +$152K +37,886 +68%
American Century Companies
8
American Century Companies
Missouri
$202K +$130K +32,263 +115%
Squarepoint
9
Squarepoint
New York
$201K +$102K +25,278 +73%
DC
10
Diametric Capital
Massachusetts
$188K +$112K +27,846 +99%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$188K +$225K +56,000 New
State Street
12
State Street
Massachusetts
$177K
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$165K +$85.6K +21,318 +75%
BCM
14
Bridgeway Capital Management
Texas
$139K +$167K +41,500 New
William Blair & Company
15
William Blair & Company
Illinois
$111K
LPL Financial
16
LPL Financial
California
$110K +$132K +32,804 New
TCOT
17
Trust Company of Toledo
Ohio
$104K -$5.77K -1,436 -4%
Northern Trust
18
Northern Trust
Illinois
$103K -$1.19K -297 -1%
Comerica Bank
19
Comerica Bank
Texas
$101K +$120K +30,000 New
Morgan Stanley
20
Morgan Stanley
New York
$98.2K -$6.1K -1,520 -5%
SWP
21
Stratos Wealth Partners
Ohio
$80.1K -$101K -25,270 -51%
Osaic Holdings
22
Osaic Holdings
Arizona
$72.1K -$45.1K -11,235 -34%
OSAM
23
O'Shaughnessy Asset Management
Connecticut
$60.8K +$26.6K +6,612 +57%
CAPTRUST Financial Advisors
24
CAPTRUST Financial Advisors
North Carolina
$60.3K -$4 -1 -0%
PCM
25
Prelude Capital Management
New York
$60.3K +$72.3K +17,996 New

IRD Hedge Fund Activity: Q3 2023 in Review

49 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2023, worth a combined $12.6M — down 21% from $16M a quarter earlier.

Fund positioning in IRD was balanced in Q3 2023: 11 funds opened new positions, 11 closed out, 11 added to existing stakes and 12 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $225K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $432K sold.

  • 49 institutional investors held Opus Genetics (IRD) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $12.6M of Opus Genetics stock for Q3 2023, down 21% quarter-over-quarter.
  • 11 funds opened new Opus Genetics positions in Q3 2023 and 11 closed out, a net change of 0 holders.
  • The largest Opus Genetics buyer in Q3 2023 was Susquehanna International Group, an estimated $225K added.
  • The largest Opus Genetics seller in Q3 2023 was Renaissance Technologies, an estimated $432K sold.

Based on aggregated 13F filings for Q3 2023.